Evidence map›Paper›PMID 38233090›Full record

ArticleBriefings in bioinformatics2023

Unsupervised and supervised AI on molecular dynamics simulations reveals complex characteristics of HLA-A2-peptide immunogenicity.

Jeffrey K Weber, Joseph A Morrone, Seung-Gu Kang, Leili Zhang, Lijun Lang, Diego Chowell, Chirag Krishna, Tien Huynh, Prerana Parthasarathy, Binquan Luan and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Briefings in bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Jeffrey K WeberIBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598USA.ORCID 0000-0002-5241-9036
Joseph A MorroneIBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598USA.ORCID 0000-0001-8550-4854
Seung-Gu KangIBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598USA.
Leili ZhangIBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598USA.
Lijun LangIBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598USA.
Diego ChowellPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Chirag KrishnaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Tien HuynhIBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598USA.
Prerana ParthasarathyCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44195USA.
Binquan LuanIBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598USA.
Tyler J AlbanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44195USA.
Wendy D CornellIBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598USA.
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44195USA.
IBM Research - Thomas J. Watson Research Center · USCleveland Clinic · USBroad Institute · USIcahn School of Medicine at Mount Sinai · US

Funding

TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCER35CA232097 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY · 2018 to 2024
$7.0M
Elucidating genetics of response to immune checkpoint blockade in lung cancerR01CA205426 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHAN, TIMOTHY AN-THY, RIZVI, NAIYER A · 2017 to 2021
$3.2M
NCI NIH HHS R35 CA232097NIH HHS R01 CA205426
6 · The paper itself

Abstract

Immunologic recognition of peptide antigens bound to class I major histocompatibility complex (MHC) molecules is essential to both novel immunotherapeutic development and human health at large. Current methods for predicting antigen peptide immunogenicity rely primarily on simple sequence representations, which allow for some understanding of immunogenic features but provide inadequate consideration of the full scale of molecular mechanisms tied to peptide recognition. We here characterize contributions that unsupervised and supervised artificial intelligence (AI) methods can make toward understanding and predicting MHC(HLA-A2)-peptide complex immunogenicity when applied to large ensembles of molecular dynamics simulations. We first show that an unsupervised AI method allows us to identify subtle features that drive immunogenicity differences between a cancer neoantigen and its wild-type peptide counterpart. Next, we demonstrate that a supervised AI method for class I MHC(HLA-A2)-peptide complex classification significantly outperforms a sequence model on small datasets corrected for trivial sequence correlations. Furthermore, we show that both unsupervised and supervised approaches reveal determinants of immunogenicity based on time-dependent molecular fluctuations and anchor position dynamics outside the MHC binding groove. We discuss implications of these structural and dynamic immunogenicity correlates for the induction of T cell responses and therapeutic T cell receptor design.

Indexed as

HLA-A2 AntigenMolecular Dynamics SimulationArtificial IntelligenceHistocompatibility Antigens Class IHumansPeptidesProtein BindingHistocompatibility Antigens Class IHLA-A2 AntigenPeptidescancer immunotherapygraph convolutionsimmunogenicityMarkov modelsMHC–peptide complexmolecular dynamics

Identifiers

PMID38233090
PMCPMC10793977
OpenAlexW4390939503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.